Category - AlaheTube
the exact mechanism of differential bcl2 protein expression in breast cancer is complex. Bcl2 is expressed in normal breast glandular epithelium and is known to be upregulated by oestrogen, possibly as a direct result of transcriptional induction (wang and phang, 1995 leung and wang, 1999). therefore, bcl2-positive expression in breast cancer may be considered a sign of estrogen receptor (er) functional activity and is associated with the outcomes 2,4,5,6,7. Damage to dna can render a cell useless, or even harmful to an organism. Apoptosis, or programmed cell death, evolved as a rapid and irreversible process to efficiently eliminate dysfunctional cells. 1 a hallmark of cancer is the ability of malignant cells to evade apoptosis. 2 cancer cells exhibit many characteristics that would readily trigger apoptosis in healthy cellsfor example, they. breast cancer is heterogeneous and the existing prognostic classifiers are limited in accuracy, leading to unnecessary treatment of numerous women. non-phosphorylated bcl2 inhibits apoptosis, and bax homodimers normally cause apoptosis bax can bind to and inhibit non-phosphorylated bcl2, promoting apoptosis epstein-barr virus latent membrane protein-1 (lmp-1) interacts with bcl2 promoter, leading to prolonged lifespan for b cells. A phase 1b dose-escalation and expansion study of the bcl-2 inhibitor venetoclax combined with tamoxifen in er and bcl-2positive metastatic breast cancer (mbc). The prosurvival protein bcl-2 is frequently overexpressed in estrogen receptor (er)-positive breast cancer. We have generated er-positive primary breast tumor xenografts that recapitulate the primary tumors and demonstrate that the bh3 mimetic abt-737 markedly improves tumor response to the antiestrogen tamoxifen. Although bcl2 has occasionally been suggested as a candidate prognostic factor for breast cancer, it is still not accepted as a prognostic factor. Combined b-cell lymphoma 2 (bcl2) and ki67 expression for breast cancer prognostication has been proposed recently. However, the combinatorial relationship with patient outcome, clinico-pathologic features, and various biomarkers has not been fully explored. Bcl2 and ki67 expression were examined in a large cohort of breast cancers.